Using fecal microbiota transplantation to improve immunotherapy response in melanoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates whether transferring the microbiota from either responding or non-responding patients can enhance the effectiveness of immunotherapy in patients with advanced melanoma who have not responded to immune checkpoint inhibitors. It is a randomized double-blind intervention involving fecal microbiota transplantation (FMT) from donors who have either responded or not responded to anti-PD-1 therapy. Patients will undergo bowel clearance and receive FMT via esophagogastroduodenoscopy, followed by continued treatment with immune checkpoint inhibitors. The study aims to determine if the microbiota can influence treatment outcomes in refractory metastatic melanoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients should be 18 years or older
* Patients have pathologically confirmed advanced stage cutaneous melanoma (stage III or IV) requiring systemic treatment with anti-PD-1

  * In case of stage IV disease, only patients with M1a or M1b disease are eligible.
* Patients have confirmed disease progression (≥20% increase according to RECIST1.1) on two consecutive scans with a four week interval while on anti-PD-1 treatment, of which the second scan has to be performed within 3 weeks prior to signing informed consent.
* Patients must have measurable disease per RECIST 1.1 criteria
* Patients have an ECOG performance status of 0-1 (appendix D)
* Patients have a life expectancy of \>3 months
* Patients have adequate organ function as determined by standard-of-care pre-checkpoint inhibitor infusion lab (including serum ALAT/ASAT less than three times the upper limit of normal (ULN); serum creatinine clearance 50ml/min or higher; total bilirubin less than or equal to 20 micromol/L, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 50 micromol/L)
* Patients have an LDH level of ≤1 times ULN
* Patients of both genders must be willing to use a highly effective method of birth control during treatment
* Patients must be able to understand and sign the Informed Consent document

Exclusion Criteria:

* Patients with acral, uveal or mucosal melanoma, or patients with an unknown primary
* Patients who have received treatment for their melanoma other than anti-PD-1 treatment.
* Stage IV patients with M1c or M1d disease.
* Patients with autoimmune diseases: patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease, are excluded from this study (except Hashimoto thyroiditis, vitiligo, history of psoriasis, but no active disease)
* Patients with any grade 3 or 4 immune-related adverse events still requiring active immunosuppressive medication, apart from endocrinopathies that are stable under hormone replacement therapy. Patients who had developed grade 3-4 immune related toxicity, which has reverted to grade I with immunosuppressive drugs and who are off immunosuppression at least two weeks prior to enrollment are eligible
* Patients with brain or LM metastasis.
* Patients with an elevated LDH level
* Patients that have undergone major gastric/esophageal/bowel surgery (like Wipple, subtotal colectomy)
* Severe food allergy (e.g. nuts, shellfish)
* Patients with a swallowing disorder or expected bowel passage problems (ileus, fistulas, perforation)
* Severe dysphagia with incapability of swallowing 2 liters of bowel lavage
* Patients with a life expectancy of less than three months
* Patients with severe cardiac or pulmonary comorbidities (per judgement of the investigator)
* Women who are pregnant or breastfeeding
* Patients with any active systemic infections, coagulation disorders or other active major medical illnesses
* Patients with other malignancies, except adequately treated and a cancer-related life-expectancy of more than 5 years
* Patients who received treatment with antibiotics in the three months prior to study enrolment, or patients we are expected to receive systemic antibiotics during the course of this study

Where it's running

• Antoni van Leeuwenhoek
  Amsterdam, Netherlands Recruiting

Study contacts

• Principal investigator: John Haanen, Prof — Medical Oncologist
• Study coordinator: John Haanen, Prof
• Email: j.haanen@nki.nl
• Phone: +31205129111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Cyclophosphamide and Pembrolizumab for advanced melanoma treatment

  This study is testing if a combination of Cyclophosphamide and Pembrolizumab can help people with advanced melanoma who haven't responded to other treatments feel better and improve their health.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06771544

• Long-term follow-up for patients treated with Miltenyi CAR T therapies

  This study looks at how well Miltenyi CAR T cell therapies work and their long-term safety for patients, especially kids, who have already been treated.

  Recruiting at 2 sites Miltenyi Biomedicine GmbH · Berlin and 6 other locations · NCT06508775

• Neoadjuvant and adjuvant immunotherapy for advanced melanoma

  This study is testing if a new type of immunotherapy can help people with advanced melanoma do better before and after surgery.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06295159

• Evaluating new treatments for advanced melanoma with pembrolizumab

  This study is testing new treatment combinations for patients with advanced melanoma who haven't responded to previous therapies to see if they can improve their chances of survival.

  Recruiting at 5 sites Phase 2 Philogen S.p.A. · Hartford, Connecticut and 6 other locations · NCT06284590

• Gene-modified TIL therapy (ADP-TILIL7) for locally advanced or metastatic melanoma

  This study will test whether a patient's own tumor-infiltrating lymphocytes, gene-modified to produce IL-7, can be safely given to adults with unresectable or metastatic melanoma who have progressed after PD-1 therapy.

  Recruiting at 2 sites Phase 1 Herlev Hospital · Herlev and 1 other locations · NCT06204991

• Analyzing PET scans and blood samples in melanoma patients receiving immunotherapy

  This study is testing if early PET scans and blood tests can help predict how well immunotherapy works for people with advanced melanoma.

  Recruiting University of Wisconsin, Madison · Madison, Wisconsin · NCT06199713

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.